Glioblastoma (GBM) represents 14.9% of all primary brain tumors and is considered one of the most aggressive types of brain tumors. Even after resection, radiation and chemotherapy, the tumor often times grows back and gives a median survival rate of 15 months.
Medulloblastoma is a fast-growing, high-grade tumor that is primarily found in children. While there are currently four recognized subtypes of this tumor, a recent study found there are seven different subgroups of this brain tumor that all have their own characteristics.
The latest Annual Report to the Nation on the Status of Cancer from 1975-2014 was released early online in the Journal of the National Cancer Institute. Overall, cancer death rates declined in men, women, and children for all major race and ethnic groups. However, death rates for cancers of the liver, pancreas, and brain increased in men.
Professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), William Stallcup, PhD, published an overview about a protein that plays an important role in glioma, called NG2. Gliomas represent 24.7% of all primary brain tumors and 74.6% of all malignant brain tumors.
A new genetic study uncovered genetic variants associated with an increased risk of glioma. Gliomas are brain tumors that grows from the brain’s glial cells and can arise as Grade IV glioblastomas or as lower grade gliomas.
Medulloblastoma is the most common malignant pediatric brain tumor. Researchers at St. Jude Children’s Research Hospital are interested in how important a cancer-related protein called Ezh2 can be in both driving and suppressing this tumor type.